EXAI

Exscientia plc (EXAI) | Rumor.io

Exscientia

EXAI

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about EXAI?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Dec 2

EXAI (Exscientia plc) has a catalyst incoming on Dec 9 with CDK7 program readouts.
The FDA has no approved drugs in this space yet, which could lead to significant movement if the news is positive.
Exscientia has 10 drugs in the pipeline and acquired AI-drug play capabilities through its Exscientia acquisition.

Generated by AI

Sentiment

Of the messages about EXAI that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100%	100% +12.93
Bearish	—	—	0%	0% -12.93

Bullish· Nov 29

Exscientia's established presence and promising prospects make it a more attractive investment opportunity compared to Isomorphic Labs.
Exscientia's acquisition by Recursion Pharmaceuticals adds to its growth potential, making it an even more compelling bet in the market.
Exscientia's established track record and Recursion's backing position it as a leading player in the industry, offering investors a strong potential for returns.

Bearish· Sep 21

$EXAI is experiencing high volatility, with no clear reason for its recent drop of over 10%.
The stock's price is likely to fall to $11 in a few weeks, as investors are skeptical about the company's future prospects.
The recent Merck deal may not be as beneficial to $EXAI as investors think, with many believing that the company will struggle to meet its milestones and may not benefit from its own research.

Generated by AI

Topics

Of the messages about EXAI that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	0%	0%
Announcements	—	—	100%	97.83%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0%
Macro	—	—	0%	0%
Technical Analysis	—	—	0%	2.17%

Sep 20

Exscientia plc ($EXAI) has formed a new AI-driven drug discovery collaboration with Merck KGaA, combining their AI-driven precision design capabilities with Merck's expertise and clinical capabilities.
The collaboration has the potential to receive up to $674 million in milestone payments, along with royalties on product sales, and has already led to a $20 million upfront payment from Merck.
Exscientia's shares have rallied by up to 30.4% in pre-market trading following the announcement, with investors seeing the deal as a validation of the company's approach to AI-driven drug discovery.

Generated by AI

Community

Of the messages about EXAI, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	16.67%	0.52%
Newcomers	—	—	83.33%	99.48%

Regulars· Sep 20

Exscientia has partnered with Merck KGaA to combine their AI-driven precision design capabilities with Merck's oncology and I&I expertise, clinical capabilities, and funding.
The partnership will provide $20M upfront and $674M total funding to Exscientia, with a focus on oncology, neuroinflammation, and immunology.
Exscientia's shares have rallied significantly, increasing by 30.4% pre-market, following the announcement of the lucrative deal with Merck KGaA.

Newcomers· Sep 21

$EXAI spiked 10% for no clear reason, possibly due to a big fund exiting or a deal with Merck.
The Merck deal may give the company significant control over Exscientia's future, potentially affecting its stock price.
Some investors believe the stock's price increase is unsustainable and that the company's research may not meet its milestones.

Generated by AI

News

MEDDDICAL Announces RWE Strategy Advisory for Biotech Clinical Development

MEDDDICAL has officially launched a new, comprehensive RWE advisory service catering to the rapidly evolving needs of biotech companies in 2026....

2mo agomarkets.businessinsider.com

Also Discussed

Investors talking about EXAI also mention

#	Name	Attention
1	Recursion Pharmaceuticals, Inc. Class A Common StockRXRX	0.01%+0
2	Schrödinger, Inc.SDGR	0%-0.01
3	Relay Therapeutics Inc.RLAY	0%new
4	AbCellera Biologics Inc.ABCL	0.24%-0.06
5	Caribou Biosciences, Inc.CRBU	0%0
6	Absci CorporationABSI	0%+0
7	Beam Therapeutics IncBEAM	0.02%+0.02
8	Prime Medicine, Inc.PRME	0%-0.01
9	C4 Therapeutics IncCCCC	0%new
10	VERV - Verve Therapeutics, Inc.	——

Exscientia plc

Location

Social

What share of all stock conversation is about EXAI?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Dec 2

EXAI (Exscientia plc) has a catalyst incoming on Dec 9 with CDK7 program readouts.
The FDA has no approved drugs in this space yet, which could lead to significant movement if the news is positive.
Exscientia has 10 drugs in the pipeline and acquired AI-drug play capabilities through its Exscientia acquisition.

Generated by AI

Sentiment

Of the messages about EXAI that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100%	100% +12.93
Bearish	—	—	0%	0% -12.93

Bullish· Nov 29

Exscientia's established presence and promising prospects make it a more attractive investment opportunity compared to Isomorphic Labs.
Exscientia's acquisition by Recursion Pharmaceuticals adds to its growth potential, making it an even more compelling bet in the market.
Exscientia's established track record and Recursion's backing position it as a leading player in the industry, offering investors a strong potential for returns.

Bearish· Sep 21

$EXAI is experiencing high volatility, with no clear reason for its recent drop of over 10%.
The stock's price is likely to fall to $11 in a few weeks, as investors are skeptical about the company's future prospects.
The recent Merck deal may not be as beneficial to $EXAI as investors think, with many believing that the company will struggle to meet its milestones and may not benefit from its own research.

Generated by AI

Topics

Of the messages about EXAI that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	0%	0%
Announcements	—	—	100%	97.83%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0%
Macro	—	—	0%	0%
Technical Analysis	—	—	0%	2.17%

Sep 20

Exscientia plc ($EXAI) has formed a new AI-driven drug discovery collaboration with Merck KGaA, combining their AI-driven precision design capabilities with Merck's expertise and clinical capabilities.
The collaboration has the potential to receive up to $674 million in milestone payments, along with royalties on product sales, and has already led to a $20 million upfront payment from Merck.
Exscientia's shares have rallied by up to 30.4% in pre-market trading following the announcement, with investors seeing the deal as a validation of the company's approach to AI-driven drug discovery.

Generated by AI

Community

Of the messages about EXAI, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	16.67%	0.52%
Newcomers	—	—	83.33%	99.48%

Regulars· Sep 20

Exscientia has partnered with Merck KGaA to combine their AI-driven precision design capabilities with Merck's oncology and I&I expertise, clinical capabilities, and funding.
The partnership will provide $20M upfront and $674M total funding to Exscientia, with a focus on oncology, neuroinflammation, and immunology.
Exscientia's shares have rallied significantly, increasing by 30.4% pre-market, following the announcement of the lucrative deal with Merck KGaA.

Newcomers· Sep 21

$EXAI spiked 10% for no clear reason, possibly due to a big fund exiting or a deal with Merck.
The Merck deal may give the company significant control over Exscientia's future, potentially affecting its stock price.
Some investors believe the stock's price increase is unsustainable and that the company's research may not meet its milestones.

Generated by AI

Exscientia

Social

Dec 2

Bullish· Nov 29

Bearish· Sep 21

Sep 20

Regulars· Sep 20

Newcomers· Sep 21

MEDDDICAL Announces RWE Strategy Advisory for Biotech Clinical Development

Also Discussed

Exscientia plc

Company Information

Location

MEDDDICAL Announces RWE Strategy Advisory for Biotech Clinical Development

Also Discussed

Social

Dec 2

Bullish· Nov 29

Bearish· Sep 21

Sep 20

Regulars· Sep 20

Newcomers· Sep 21